Literature DB >> 23902243

Personalized therapy for breast cancer: a dream or a reality?

Dimitrios Zardavas1, Lina Pugliano, Martine Piccart.   

Abstract

Breast cancer oncology represents one of the disciplines where personalized cancer medicine has been most actively pursued. The class-discovery studies conceptually advanced the field, underlining the molecular heterogeneity governing this common disease. The advent of high-throughput molecular profiling technologies holds great promise for the advance of all aspects of personalized cancer medicine, namely accurate prognostication, prediction of response to common systemic therapies and individualized monitoring of the disease. Moreover, an ever-expanding arsenal of targeted therapeutic compounds under clinical development, coupled with emerging powerful tools for comprehensive molecular and functional characterization, pose significant promise for improved clinical outcomes for breast cancer patients. Interrogation of the germline genetic variation offers further promise towards tailoring of breast cancer management. Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23902243     DOI: 10.2217/fon.13.57

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  13 in total

Review 1.  Clinical management of breast cancer heterogeneity.

Authors:  Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

Review 2.  Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Authors:  Z Fadoukhair; D Zardavas; M A Chad; T Goulioti; P Aftimos; M Piccart
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

3.  Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction.

Authors:  Xiang Gao; Baojia Sun; Yonglian Hou; Lilin Liu; Jianan Sun; Fanxing Xu; Dahong Li; Huiming Hua
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Molecular fingerprinting catches responders to therapeutic agents.

Authors: 
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

5.  The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Authors:  Marion Maetens; David Brown; Sherene Loi; Christos Sotiriou; Alexandre Irrthum; Philippe Aftimos; Giuseppe Viale; Sibylle Loibl; Jean-François Laes; Peter J Campbell; Alastair Thompson; Javier Cortes; Sabine Seiler; Sara Vinnicombe; Mafalda Oliveira; Françoise Rothé; Yacine Bareche; Debora Fumagalli; Dimitrios Zardavas; Christine Desmedt; Martine Piccart
Journal:  NPJ Breast Cancer       Date:  2017-06-29

Review 6.  The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches.

Authors:  Felipe Ades; Konstantinos Tryfonidis; Dimitrios Zardavas
Journal:  Ecancermedicalscience       Date:  2017-06-08

7.  Patient-reported outcomes in breast cancer FDA drug labels and review documents.

Authors:  Kyungwan Hong; Kayleigh R Majercak; Ester Villalonga-Olives; Eleanor M Perfetto
Journal:  J Patient Rep Outcomes       Date:  2021-04-21

Review 8.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

Review 9.  The AURORA initiative for metastatic breast cancer.

Authors:  D Zardavas; M Maetens; A Irrthum; T Goulioti; K Engelen; D Fumagalli; R Salgado; P Aftimos; K S Saini; C Sotiriou; P Campbell; P Dinh; G von Minckwitz; R D Gelber; M Dowsett; A Di Leo; D Cameron; J Baselga; M Gnant; A Goldhirsch; L Norton; M Piccart
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

10.  New generation of breast cancer clinical trials implementing molecular profiling.

Authors:  Dimitrios Zardavas; Martine Piccart-Gebhart
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.